Patents by Inventor Enyu Ding

Enyu Ding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acid vector
    Patent number: 10626413
    Abstract: The present invention provides a nucleic acid vector referred to as pVec constructed through molecular biotechnologies. pVec contains CMV enhancer/promoter, T7 promoter, 5?UTR, MCS, 3?UTR, poly A (120A)-TTATT, BGH poly (A) signal, kanamycin resistance gene and pUC origin, etc. So pVec can be used as a vector for both DNA vaccines or therapeutic drugs and mRNA vaccines or mRNA therapeutic drugs. The 5?UTR, 3?UTR and poly A (120A)-TTATT of pVec can be added to the 5? and 3? ends of the in vitro transcribed mRNA respectively and further stabilize the transcribed mRNA. The present invention also provides the constructed pVec-GM-CSF, pVec-hIL-12 and pVAX1-hIL-12, which are used for evaluating the benefits of pVec.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: April 21, 2020
    Inventor: Enyu Ding
  • An mRNA cancer vaccine encoding human GM-CSF fused to multiple tandem epitopes
    Publication number: 20190076460
    Abstract: The present invention provides an mRNA cancer vaccine encoding human GM-CSF fused to multiple tandem epitopes. pVec-GM-CSF-hTes encoding human GM-CSF fused to three tandem hTERT epitopes, pVec-GMKE encoding human GM-CSF fused to three tandem epitopes respectively from MUC1, Kras and EGFR, pVec-hIL-12 encoding human interleukin-12 are respectively constructed, and used as templates for generating the corresponding in vitro transcribed mRNAs, which are mixed together as an mRNA cancer vaccine. This mRNA cancer vaccine contains human GM-CSF used as an immune adjuvant, multiple tandem epitopes constituting as multi-epitope cancer antigens and hIL-12 used to enhance the immunotherapeutic effects.
    Type: Application
    Filed: February 22, 2017
    Publication date: March 14, 2019
    Inventor: Enyu Ding
  • Novel nucleic acid vector
    Publication number: 20170233761
    Abstract: The present invention provides a nucleic acid vector referred to as pVec constructed through molecular biotechnologies. pVec contains CMV enhancer/promoter, T7 promoter, 5?UTR, MCS, 3?UTR, poly A (120A)-TTATT, BGH poly (A) signal, kanamycin resistance gene and pUC origin, etc. So pVec can be used as a vector for both DNA vaccines or therapeutic drugs and mRNA vaccines or mRNA therapeutic drugs. The 5?UTR, 3?UTR and poly A (120A)-TTATT of pVec can be added to the 5? and 3? ends of the in vitro transcribed mRNA respectively and further stabilize the transcribed mRNA. The present invention also provides the constructed pVec-GM-CSF, pVec-hIL-12 and pVAX1-hIL-12, which are used for evaluating the benefits of pVec.
    Type: Application
    Filed: January 15, 2016
    Publication date: August 17, 2017
    Inventor: Enyu Ding